Deo YM - Search Results

1

Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody, MDX-210.

Watanabe M, Wallace PK, Keler T, Deo YM, Akewanlop C, Hayes DF. Watanabe M, et al. Among authors: deo ym. Breast Cancer Res Treat. 1999 Feb;53(3):199-207. doi: 10.1023/a:1006145507567. Breast Cancer Res Treat. 1999. PMID: 10369066

2

Bispecific antibody-dependent cellular cytotoxicity of HER2/neu-overexpressing tumor cells by Fc gamma receptor type I-expressing effector cells.

Keler T, Graziano RF, Mandal A, Wallace PK, Fisher J, Guyre PM, Fanger MW, Deo YM. Keler T, et al. Among authors: deo ym. Cancer Res. 1997 Sep 15;57(18):4008-14. Cancer Res. 1997. PMID: 9307286

3

Phase I pilot trial of the bispecific antibody MDXH210 (anti-Fc gamma RI X anti-HER-2/neu) in patients whose prostate cancer overexpresses HER-2/neu.

Schwaab T, Lewis LD, Cole BF, Deo Y, Fanger MW, Wallace P, Guyre PM, Kaufman PA, Heaney JA, Schned AR, Harris RD, Ernstoff MS. Schwaab T, et al. J Immunother. 2001 Jan-Feb;24(1):79-87. doi: 10.1097/00002371-200101000-00009. J Immunother. 2001. PMID: 11211151 Clinical Trial.

4

Bispecific molecules directed to the Fc receptor for IgA (Fc alpha RI, CD89) and tumor antigens efficiently promote cell-mediated cytotoxicity of tumor targets in whole blood.

Deo YM, Sundarapandiyan K, Keler T, Wallace PK, Graziano RF. Deo YM, et al. J Immunol. 1998 Feb 15;160(4):1677-86. J Immunol. 1998. PMID: 9469424

5

Characterization of a novel bispecific antibody that mediates Fcgamma receptor type I-dependent killing of tumor-associated glycoprotein-72-expressing tumor cells.

Russoniello C, Somasundaram C, Schlom J, Deo YM, Keler T. Russoniello C, et al. Among authors: deo ym. Clin Cancer Res. 1998 Sep;4(9):2237-43. Clin Cancer Res. 1998. PMID: 9748144

6

Differential effect of cytokine treatment on Fc alpha receptor I- and Fc gamma receptor I-mediated tumor cytotoxicity by monocyte-derived macrophages.

Keler T, Wallace PK, Vitale LA, Russoniello C, Sundarapandiyan K, Graziano RF, Deo YM. Keler T, et al. Among authors: deo ym. J Immunol. 2000 Jun 1;164(11):5746-52. doi: 10.4049/jimmunol.164.11.5746. J Immunol. 2000. PMID: 10820252

7

Development of a trispecific antibody conjugate that directs two distinct tumor-associated antigens to CD64 on myeloid effector cells.

Somasundaram C, Sundarapandiyan K, Keler T, Deo YM, Graziano RF. Somasundaram C, et al. Among authors: deo ym. Hum Antibodies. 1999;9(1):47-54. Hum Antibodies. 1999. PMID: 10331185

8

Bispecific antibody-mediated destruction of Hodgkin's lymphoma cells.

Sundarapandiyan K, Keler T, Behnke D, Engert A, Barth S, Matthey B, Deo YM, Graziano RF. Sundarapandiyan K, et al. Among authors: deo ym. J Immunol Methods. 2001 Feb 1;248(1-2):113-23. doi: 10.1016/s0022-1759(00)00347-1. J Immunol Methods. 2001. PMID: 11223073

9

Targeting tumor cell destruction with CD64-directed bispecific fusion proteins.

Graziano RF, Goldstein J, Sundarapandiyan K, Somasundaram C, Keler T, Deo YM. Graziano RF, et al. Among authors: deo ym. Cancer Immunol Immunother. 1997 Nov-Dec;45(3-4):124-7. doi: 10.1007/s002620050413. Cancer Immunol Immunother. 1997. PMID: 9435854 Free PMC article. No abstract available.

10

Targeting weak antigens to CD64 elicits potent humoral responses in human CD64 transgenic mice.

Keler T, Guyre PM, Vitale LA, Sundarapandiyan K, van De Winkel JG, Deo YM, Graziano RF. Keler T, et al. Among authors: deo ym. J Immunol. 2000 Dec 15;165(12):6738-42. doi: 10.4049/jimmunol.165.12.6738. J Immunol. 2000. PMID: 11120792

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

37 results

Search Page